Dealing with a cancer diagnosis can feel like you're caught in a whirlwind of treatments—appointments piling up, emotions ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and ...

Darcey Kemp, from Mobberley, had to undergo a full blood transfusion after doctors found she was battling juvenile ...

Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

Below is a roundup of health tech and digital health news you may have missed | Keep up with some of the latest headlines in ...

McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability. Read why MCK stock is a ...

When a critical care physician suddenly needs critical care, she learns as a patient everything she wishes she’d been taught ...

CheapInsurance.com examined the demographics of the uninsured population in the United States using data from the Census ...

If your tumor is benign, it won’t require treatment, but if it is malignant ... However, the following chart summarizes a few things you can watch for to see whether it’s more likely to ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...